Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1276 participants.
Also called NCT07001800
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 1,276 participants
- Sponsor
- Registry
-
NCT07001800
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT07001800. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-27 (actual); primary completion 2028-08-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
- Acronym
- KATALYST-AV
- Condition
- Moderate Aortic Valve Stenosis
- Intervention (Drug)
- Ataciguat
- Intervention (Drug)
- Placebo
- Lead sponsor
- Kardigan, Inc.
Record details
- Record id
cardio:ct-nct07001800- Content hash
e1e8f67173a52139da5cc2dc0b990ad7f1b069ae62eda2c111c389c678834eb7